Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 55Leukemia, Myeloid, Acute 38Breast Neoplasms 38Lymphoma, Large B-Cell, Diffuse 35Multiple Myeloma 31Lymphoma, Non-Hodgkin 29Burkitt Lymphoma 29Lymphoma 27Myelodysplastic Syndromes 25Triple Negative Breast Neoplasms 23Recurrence 23Hematologic Neoplasms 22Lymphoma, B-Cell 21Lymphoma, Follicular 20Melanoma 16Ovarian Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Neoplasm Metastasis 14Leukemia 14Hodgkin Disease 13Neoplasms 12Leukemia, Biphenotypic, Acute 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Neuroblastoma 11Leukemia, Myelomonocytic, Chronic 11Lymphoma, Mantle-Cell 10Graft vs Host Disease 10Carcinoma, Non-Small-Cell Lung 10Lymphoma, T-Cell, Peripheral 9

Interventions

Epirubicin 1Docetaxel 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hormone Receptor Positive HER-2 Negative Breast Cancer × Cyclophosphamide × Clear all
NCT05901428 2023-06-15

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Fudan University

Phase 3 Recruiting
1,736 enrolled
Breast

Hormone Receptor Positive HER-2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡